The Impact of Blue-Light Emitting Device on the Loss of Productivity From COVID-19 in North Carolina


Caterino M1, Silas U1, Saunders R2
1Coreva Scientific GmbH & Co. KG, Königswinter, NW, Germany, 2Coreva Scientific, Königswinter, NW, Germany

OBJECTIVES: The COVID-19 pandemic has led to substantial health and economic burdens due to loss of productivity. The blue-light emitting device RD-X19, which stimulates local immunity to expedite recovery from mild to moderate COVID-19, presents a promising intervention. Despite national economic studies on RD-X19, its value in curbing productivity loss still needs to be explored.

METHODS: We employed the Covasim framework for in-depth COVID-19 simulations, comparing Standard of Care to a scenario where RD-X19 is given to 10% of symptomatic workers aged 21-65 in North Carolina from January 2023 to January 2024. This conservative 10% value was chosen for its simplicity. Simulations were based on CDC data and assumptions on prior immunity and the absence of imported cases. Economic estimates incorporated 2022 U.S. labor statistics. Model validity was tested against 20230 CDC data.

RESULTS: RD-X19 use led to an estimated reduction of approximately 221,000 (CrI 95% [198,000, 244,000]) COVID-19 cases, preserving roughly 2.1 million working days in North Carolina. This equates to potential productivity savings of about $250 million.

CONCLUSIONS: RD-X19 integration into COVID-19 management for mild to moderate cases could significantly reduce productivity loss. Even with a moderate uptake, the economic implications are substantial, indicating potential savings in the hundreds of millions. These findings underscore the potential of RD-X19 to mitigate the socioeconomic impacts of the COVID-19 pandemic.

Conference/Value in Health Info

2023-11, ISPOR Europe 2023, Copenhagen, Denmark

Value in Health, Volume 26, Issue 11, S2 (December 2023)




Economic Evaluation, Methodological & Statistical Research

Topic Subcategory

Work & Home Productivity - Indirect Costs


Infectious Disease (non-vaccine), Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on Update my browser now